Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

BACKGROUND: This study aimed to evaluate the efficiency and prognostic factors of lenvatinib plus programmed death 1 (PD-1) blockades in patients with advanced hepatocellular carcinoma (HCC), especially for those with tumor occupation ≥50% volume of liver (TO ≥50%) or invasion in Vp4, who were exclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xuqi, Zhang, Qi, Mei, Jie, Yang, Ziliang, Chen, Minshan, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933880/
https://www.ncbi.nlm.nih.gov/pubmed/35305593
http://dx.doi.org/10.1186/s12885-022-09405-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933880/
https://www.ncbi.nlm.nih.gov/pubmed/35305593
http://dx.doi.org/10.1186/s12885-022-09405-7

Ejemplares similares